When to Refer a Prostate Cancer Patient for Treatment Abroad

Management is decided by the disease's staging and parameters: PSA level, Gleason score, and clinical stage on digital rectal examination. Survival rates vary sharply by stage - low-risk, early disease has close to a 100% cure rate, and even metastatic (stage four) patients now have meaningfully better life expectancy with appropriate treatment than with many other stage-four cancers.

Kidney transplant is the treatment of choice for renal failure, and results are best with a related, genetically matched donor. Even without a genetic match or matching blood group, plasmapheresis, an advanced technique that lowers the antigenicity of the donor organ, can still allow a transplant to proceed.

This is a misconception. The great majority of prostate operations are for benign BPH and are done endoscopically with little morbidity; patients are very satisfied. Even for cancer, with modern robotic surgery, hospital stay is just about three days, and patients are often fit to fly home within two to three weeks without a catheter.

No - this combination provides symptomatic relief rather than eradication. Tamsulosin relaxes the prostate to improve urinary flow, while finasteride can shrink the size of the prostate over time, but neither eliminates the underlying benign enlargement.

It depends entirely on the stage. Early, organ-confined disease is treated with curative intent using robotic radical prostatectomy or radiotherapy. Locally advanced disease (spread just outside the prostate but not to lymph nodes or bone) may still use surgery or radiotherapy, combined with androgen deprivation therapy. Disease that has spread more widely and is not surgically resectable is treated less aggressively, with radiotherapy plus hormone deprivation. Metastatic disease (spread to bone) is treated with intent to suppress rather than cure, using hormonal suppression (surgical orchidectomy or depot injections). Hormone-resistant disease, where the cancer no longer responds to hormone deprivation, needs chemotherapy (docetaxel) or oral agents such as abiraterone or enzalutamide.

When the local setup cannot offer the appropriate treatment for that disease stage (PET scans, radiotherapy, robotic surgery) or the patient is too frail to travel; earlier referral gives better outcomes.

It's the most specific imaging test for prostate cancer spread and is often unavailable locally, so confirming metastasis status directly affects prognosis and treatment planning.